Navigation Links
Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds

SAN DIEGO and MONTREAL, Feb. 25 /PRNewswire/ -- Speid & Associates, an international regulatory and drug development consultancy firm today announced that it has entered into a partnership with Genizon BioSciences to increase success rates of new drug compounds using Genizon's proprietary genetic platform. In this challenging economic climate in which innovative pharmaceutical and biotechnology companies have to watch every dollar that is spent on drug development, the Genizon and Speid collaboration will help to increase the ultimate success of drug development programs. Genizon's predictive techniques will also enable Speid's clients to identify and eliminate compounds with relatively low chances of success earlier than if these techniques are not used.

"As we develop effective regulatory strategies for our clients' drug candidates, I am very pleased that Genizon will work alongside us at our clients' requests," said Lorna Speid, Ph.D., president of Speid & Associates. Dr. Speid added, "I anticipate that the Genizon technology and expertise will allow our clients to re-visit compounds that may have been placed on the 'back-burner', but which may hold promise as new medications."

"We believe that we can add significant value to Speid & Associates' clients through pharmacogenomic studies and analyses using our gene discovery platform and expertise. These enable invaluable insights into drug response, and therefore improve clinical trial outcomes," said Majid Belouchi, Ph.D., founder and chief scientific officer of Genizon. He added, "We use predictive biomarkers to identify patients who are more likely to respond to a given treatment. Consequently, the combination of Genizon's proprietary gene discovery platform and Speid's expertise in regulatory affairs will assure expeditious pathways to commercialization."

About Genizon BioSciences

Genizon BioSciences Inc. is a leader in genetic solutions. Genizon discovers genes, genetic biomarkers, biochemical pathways and drug targets that are involved in human disease susceptibility and drug response. These genetic insights allow the development of predictive diagnostics that facilitate personalized medicine. Working with a network of over 1,000 clinical investigators, Genizon has recruited over 47,000 subjects in 25 common diseases, which are analyzed in a unique, integrated high throughput facility that is compliant with GCP and GLP guidelines. Discoveries are translated into clinical practice through collaborative research with academic and clinical leaders. Genizon also provides high throughput, high quality SNP genotyping, genetic analysis, gene expression and pharmacogenomics services to academic institutions, research organizations and the biopharmaceutical industry.

For more information visit:

About Speid & Associates, Inc.

Speid & Associates, Inc. is a privately held regulatory affairs and drug development consultancy based in San Diego, California. Speid & Associates assists life science companies move new chemical entities to the finish line expeditiously by developing effective global regulatory strategies for the international pharmaceutical and biotechnology industries. Speid also conducts due diligence for investors and companies.

For more information visit:

SOURCE Genizon BioSciences Inc.; Speid & Associates, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
5. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
8. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
9. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
10. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
11. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):